Incidence of grade 3-5 infusional toxicity Within 48 Hours After iTregs Administration [clinicaltrials_resource:25ab5f3315a1b913b84c009e336357a8]
Targeted adverse events and unexpected events not explained by the PBSCT or disease will be collected [(1-4 hours after the iTreg infusion and before the PBSCT at day 0) and 24 hours and 48 hours after the iTreg infusion (+/- 2 hours)]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Incidence of grade 3-5 infusional toxicity Within 48 Hours After iTregs Administration [clinicaltrials_resource:25ab5f3315a1b913b84c009e336357a8]
Targeted adverse events and unexpected events not explained by the PBSCT or disease will be collected [(1-4 hours after the iTreg infusion and before the PBSCT at day 0) and 24 hours and 48 hours after the iTreg infusion (+/- 2 hours)]
Bio2RDF identifier
25ab5f3315a1b913b84c009e336357a8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:25ab5f3315a1b913b84c009e336357a8
measure [clinicaltrials_vocabulary:measure]
Incidence of grade 3-5 infusional toxicity
time frame [clinicaltrials_vocabulary:time-frame]
Within 48 Hours After iTregs Administration
description
Targeted adverse events and un ...... iTreg infusion (+/- 2 hours)]
identifier
clinicaltrials_resource:25ab5f3315a1b913b84c009e336357a8
title
Incidence of grade 3-5 infusional toxicity Within 48 Hours After iTregs Administration
@en
type
label
Incidence of grade 3-5 infusio ...... b5f3315a1b913b84c009e336357a8]
@en